FDA Approves Neupro Transdermal Patch Against Parkinson's Disease
Filed in archive Drugs, Vaccines and Therapeutics on May 10, 2007
The US FDA has approved Neupro® (Rotigotine Transdermal System) for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease (PD). Neupro is a once-daily non-ergolinic dopamine agonist skin patch developed by Schwarz Pharma.
"This is an important step forward for the patients suffering from Parkinson's disease. Following approval and launch within Europe, Neupro will now be available for patients in the USA", comments Iris Loew-Friedrich, MD, PhD,
CSO SCHWARZ PHARMA AG. "We intend to submit a supplemental New Drug Application for the treatment of advanced Parkinson's disease to the FDA by the end of 2007."
Rotigotine is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning.
Source: Schwarz Pharma (pdf)
CSO SCHWARZ PHARMA AG. "We intend to submit a supplemental New Drug Application for the treatment of advanced Parkinson's disease to the FDA by the end of 2007."
Tags: FDA Neupro parkinson+disease schwarz+pharma pharma biotech transdermal+patch patch+against
Vote for FDA Approves Neupro Transdermal Patch Against Parkinson's Disease:
|
Rating: 9.50 out of 2 vote(s) cast.
|
Response from:
Edward
(05/16/07 6:23am)
Response from:
Johnson Chen
(01/16/08 9:53am)
HealthLat is inviting patients who take Neupro, and physicians who prescribe it to report their experiences with the new drug. Your experiences will help patients needed and make money for you.
You are also welcome to check how Neupro has been used by other patients. It is free.
For details, please visit: http://www.healthlat.com
You are also welcome to check how Neupro has been used by other patients. It is free.
For details, please visit: http://www.healthlat.com
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells
as well.
It's very exciting, especially when you take into account the current success Rotigotine is having with Parkinson's patients in the European market.
Barring anything unseen, it looks like we'll have the convenience of ONE daily dose by June!!!